Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for ESA Responsiveness in Anemic CKD
NCT06897605Phase 2Recruiting
- Sponsor
- Mansoura University
- Start
- Apr 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dapagliflozin in anemia of chronic kidney disease (CKD-A) (2 arms), sponsored by Mansoura University. Primary endpoint: Change in Erythropoiesis stimulating agent therapy dose at 12 weeks. Started Apr 2025; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT06897605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06897605.